Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Net Cash Flow: 2018-2024

Historic Net Cash Flow for Revolution Medicines (RVMD) over the last 7 years, with Dec 2024 value amounting to -$152.4 million.

  • Revolution Medicines' Net Cash Flow fell 146.74% to -$184.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.1 million, marking a year-over-year increase of 111.59%. This contributed to the annual value of -$152.4 million for FY2024, which is 128.43% down from last year.
  • Latest data reveals that Revolution Medicines reported Net Cash Flow of -$152.4 million as of FY2024, which was down 128.43% from $536.0 million recorded in FY2023.
  • In the past 5 years, Revolution Medicines' Net Cash Flow registered a high of $536.0 million during FY2023, and its lowest value of -$152.4 million during FY2024.
  • Moreover, its 3-year median value for Net Cash Flow was $52.9 million (2022), whereas its average is $145.5 million.
  • In the last 5 years, Revolution Medicines' Net Cash Flow soared by 983.88% in 2022 and then plummeted by 128.43% in 2024.
  • Over the past 5 years, Revolution Medicines' Net Cash Flow (Yearly) stood at $88.5 million in 2020, then slumped by 94.48% to $4.9 million in 2021, then soared by 983.88% to $52.9 million in 2022, then soared by 913.00% to $536.0 million in 2023, then crashed by 128.43% to -$152.4 million in 2024.